The 2013 Merck-Pfizer Diabetes Deal Now Looks Very Savvy
The Jardiance results will certainly cause physicians to consider prescribing SGLT2 inhibitors over other classes of drugs.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: John LaMattina Source Type: news
More News: Diabetes | Empagliflozin | Endocrinology | Jardiance | Merck | Pfizer | Pharmaceuticals | SGLT2 Inhibitors